Wine Cellar Innovations

Cellarity Named a Top Place to Work for 2023 by The Boston Globe

Retrieved on: 
Monday, December 4, 2023
Software, Research, Professional Services, Pharmaceutical, Technology, Genetics, Artificial Intelligence, Publishing, Science, Biotechnology, Communications, Human Resources, Health, BBJ, Data science, Flagship Pioneering, Patient, Boston Business School, Systems biology, Drug discovery, Work, AI, Pharming, Drug development, Pharmaceutical industry, Wine Cellar Innovations

Top Places to Work recognizes the most admired workplaces in the state voted on by the people who know them best – their employees.

Key Points: 
  • Top Places to Work recognizes the most admired workplaces in the state voted on by the people who know them best – their employees.
  • The rankings in Boston Globe’s Top Places to Work are based on confidential survey information collected from more than 137,000 individuals at 341 Massachusetts organizations.
  • The survey measures employee opinions about their company's direction, execution, connection, management, work, pay and benefits, and engagement.
  • This achievement was based on the input from Cellarity team members who responded to the BBJ survey asking for their anonymous feedback on Cellarity as an employer.

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023

Retrieved on: 
Tuesday, November 7, 2023
Science, Research, NR4A3, CAR, NSCLC, IND, Literature, Colorectal cancer, ROR1, G&A, Workforce, GSK plc, GAAP, Phenotype, TIL, R, Lyell, TNBC, SITC, Immunotherapy, Clinical trial, Wine Cellar Innovations, Abstract, GSK, Triple-negative breast cancer, Lung cancer, Society, Patient, Pharmaceutical industry, Vaccine, Medical imaging

An approximately 25% reduction in workforce associated with this prioritization is expected to be completed in the fourth quarter of 2023.

Key Points: 
  • An approximately 25% reduction in workforce associated with this prioritization is expected to be completed in the fourth quarter of 2023.
  • Lyell is advancing four wholly-owned product candidates with two product candidates in Phase 1 clinical development, LYL797 and LYL845.
  • Non‑GAAP G&A expenses, which exclude non-cash stock-based compensation, for the third quarter ended September 30, 2023, were $9.5 million, compared to $11.4 million for the same period in 2022.
  • The decrease in third quarter 2023 non-GAAP G&A expenses was driven by a decrease in legal, consulting and other administrative expenses.

Cellares Raises $255M Series C to Launch First Integrated Development and Manufacturing Organization (IDMO) and Pioneering Smart Factory to Meet Global Demand for Life-Saving Cell Therapies

Retrieved on: 
Wednesday, August 23, 2023
Eclipse, Smart, Workforce, Wine Cellar Innovations, Drug development, TAP, Bristol Myers Squibb, CDMO, Patient, Integrated development environment, Fourth Industrial Revolution, Growth, Cell, Robotics, SDM, Automation, Pharmaceutical industry, Mobile phone, Fine chemical

As the first IDMO, Cellares is empowering cell therapy companies to build viable businesses, remain competitive, and meet the needs of fast-growing patient populations."

Key Points: 
  • As the first IDMO, Cellares is empowering cell therapy companies to build viable businesses, remain competitive, and meet the needs of fast-growing patient populations."
  • ft. IDMO Smart Factory, located in Bridgewater, New Jersey, will be capable of producing 40,000 cell therapy batches per year[1].
  • Cellares' Smart Factories will be deployed around the world to enable the cell therapy industry to meet global patient demand.
  • The company's flexible manufacturing technology supports both autologous and allogeneic cell therapy processes and about 90% of cell therapy modalities.

Cellares Raises $255M Series C to Launch First Integrated Development and Manufacturing Organization (IDMO) and Pioneering Smart Factory to Meet Global Demand for Life-Saving Cell Therapies

Retrieved on: 
Wednesday, August 23, 2023
Eclipse, Smart, Workforce, Wine Cellar Innovations, Drug development, TAP, Bristol Myers Squibb, CDMO, Patient, Integrated development environment, Fourth Industrial Revolution, Growth, Cell, Robotics, SDM, Automation, Pharmaceutical industry, Mobile phone, Fine chemical

As the first IDMO, Cellares is empowering cell therapy companies to build viable businesses, remain competitive, and meet the needs of fast-growing patient populations."

Key Points: 
  • As the first IDMO, Cellares is empowering cell therapy companies to build viable businesses, remain competitive, and meet the needs of fast-growing patient populations."
  • ft. IDMO Smart Factory, located in Bridgewater, New Jersey, will be capable of producing 40,000 cell therapy batches per year[1].
  • Cellares' Smart Factories will be deployed around the world to enable the cell therapy industry to meet global patient demand.
  • The company's flexible manufacturing technology supports both autologous and allogeneic cell therapy processes and about 90% of cell therapy modalities.

TOMI and Cellares to Collaborate on the Integration of SteraMist iHP Technology into Revolutionary New Cell Therapy Manufacturing Solution

Retrieved on: 
Thursday, August 3, 2023
Hydrogen, Partnership, DARPA, U.S. Department of Defense Strategy for Operating in Cyberspace, Decontamination, Horsepower, Research, Doctor of Philosophy, Wine Cellar Innovations, School, Hospital, Hydrogen peroxide, Patient, Restaurant, Annual report, Police, Disinfectant, Meat, Safety, Food preservation

The Cellares Cell Shuttle is a breakthrough in automated cell therapy manufacturing, offering end-to-end automation and reducing inefficiencies.

Key Points: 
  • The Cellares Cell Shuttle is a breakthrough in automated cell therapy manufacturing, offering end-to-end automation and reducing inefficiencies.
  • Due to the critical importance of maintaining a sterile environment within the confined spaces of the Cell Shuttle, Cellares selected TOMI's patented iHP decontamination technology.
  • The SteraMist iHP technology ensures comprehensive decontamination with its small micron particles, offering advantages in efficacy and safety over other commercially available decontamination methods.
  • TOMI and Cellares began their partnership in 2021 and are now in the final stages of iHP Cell Shuttle prototypes.

Cellarity Strengthens Executive Leadership Team

Retrieved on: 
Tuesday, April 11, 2023
Research, Technology, Genetics, Other Health, Biotechnology, Pharmaceutical, Health, Science, Artificial Intelligence, Other Science, Upjohn, Georgia Tech, Pharming, Head, McKinsey & Company, Associate, Wharton School of the University of Pennsylvania, Acquisition, Chemical engineering, Indian Institutes of Technology, MMSc, Data science, Software, Corporate development, Business development, University, Therapy, Boston, Forma, Corporation, Drug discovery, Biology, IMPL, Mallinckrodt, Translational medicine, CBO, CFO, Drug development, Doctor of Philosophy, Johnson & Johnson, Harvard Medical School, Shire (pharmaceutical company), Flagship Pioneering, Novartis, Novo Nordisk, Flexion Therapeutics, Management, Pharmaceutical industry, Wine Cellar Innovations

The Cellarity platform uncovers novel actionable biology and creates non-intuitive drug candidates to address a vast array of diseases, even those with either limited or unknown targets.

Key Points: 
  • The Cellarity platform uncovers novel actionable biology and creates non-intuitive drug candidates to address a vast array of diseases, even those with either limited or unknown targets.
  • These new leadership appointments will allow Cellarity to accelerate development of its platform and progress its pipeline programs towards the clinic.
  • “Their appointments are a great complement to the already well experienced senior leadership team which includes Parul Doshi, recently promoted to Chief Data Officer.
  • Prior to joining Cellarity, he was previously Executive Medical Director in Clinical Development at Forma Therapeutics (acquired by Novo Nordisk) where he led their flagship sickle cell disease program.

LG PRESENTS EVOLVED LUXURY EXPERIENCE WITH ITS SECOND-GENERATION LG SIGNATURE LINEUP AT CES 2023

Retrieved on: 
Thursday, December 29, 2022
Living Beyond Breast Cancer, Wine, Partnership, Wine Cellar Innovations, Electronics, Quanta Computer, Inc. v. LG Electronics, Inc., Wine cellar, OLED TV, Las Vegas Convention Center, LG Electronics, LCD, CES, OLED, Timeless, LG Corporation, LG, Thermoplastic

ENGLEWOOD CLIFFS, N.J., Dec. 28, 2022 /PRNewswire/ -- LG Electronics (LG) will unveil its second-generation LG SIGNATURE home appliance lineup at CES 2023. Offering timeless design and innovative technologies for a more convenient, stylish, and sustainable life at home, the sophisticated, new products will be on show in the LG SIGNATURE zone of LG's booth under the theme of 'Live Beyond.'

Key Points: 
  • Company's Ultra-Premium Appliances Boast Cutting-Edge Technologies, Timeless Design and Outstanding Energy Efficiency
    ENGLEWOOD CLIFFS, N.J., Dec. 28, 2022 /PRNewswire/ -- LG Electronics (LG) will unveil its second-generation LG SIGNATURE home appliance lineup at CES 2023.
  • Seven years after its launch, LG SIGNATURE continues to redefine ultra-premium – delivering elegant, highly advanced appliances and living solutions that take performance, design and usability to new heights.
  • Other LG SIGNATURE products appearing in the exhibit include an air conditioner, air purifier, OLED TV and the Wine Cellar.
  • The aesthetically refined, technologically advanced products from the LG SIGNATURE lineup will be complemented in each stylish appointed interior scene by Molteni&C's stunning furniture pieces.

LG PRESENTS DIFFERENTIATED LUXURY EXPERIENCE WITH ITS SECOND-GENERATION LG SIGNATURE LINEUP AT CES 2023

Retrieved on: 
Thursday, December 29, 2022
Living Beyond Breast Cancer, Wine, Partnership, Wine Cellar Innovations, Electronics, Wine cellar, OLED TV, Las Vegas Convention Center, LG Electronics, News, LCD, CES, OLED, Timeless, HVAC, LG, Thermoplastic

SEOUL, South Korea, Dec. 29, 2022 /PRNewswire/ -- LG Electronics (LG) will unveil its second-generation LG SIGNATURE home appliance lineup at CES 2023. Offering timeless design and innovative technologies for a more convenient, stylish, and sustainable life at home, the sophisticated, new products will be on show in the LG SIGNATURE zone of LG's booth under the theme of 'Live Beyond.'

Key Points: 
  • Company's Ultra-Premium Appliances Boast Cutting-edge Technologies, Timeless Design and Outstanding Energy Efficiency
    SEOUL, South Korea, Dec. 29, 2022 /PRNewswire/ -- LG Electronics (LG) will unveil its second-generation LG SIGNATURE home appliance lineup at CES 2023.
  • Seven years after its launch, LG SIGNATURE continues to redefine ultra-premium; delivering elegant, highly-advanced appliances and living solutions that take performance, design and usability to new heights.
  • Among other LG SIGNATURE products appearing in the exhibit are an air conditioner, air purifier, OLED TV and the Wine Cellar.
  • The LG SIGNATURE zone, comprising of living room, laundry room and kitchen, has been created in partnership with Italian designer furniture brand, Molteni&C.

LG HOSTS EXCLUSIVE PERFORMANCE SERIES SHOWCASING THE BEST OF CONTEMPORARY ARTS

Retrieved on: 
Monday, November 28, 2022
Bourgeoisie, OLED, LG Gangnam Tower, Multimedia, LG Electronics, My Way, Philosophy, Yoann Bourgeois, Exhibition, Wine Cellar Innovations, Wine, Electronics, Wine cellar, LG, Manufacturing, Interior design, Entertainment

SEOUL, South Korea, Nov. 27, 2022 /PRNewswire/ -- LG Electronics (LG) brought together the world of art and technology with its ultra-premium brand, LG SIGNATURE, sponsoring two immersive performances at the LG Arts Center SEOUL in South Korea last week.

Key Points: 
  • On Behalf of Premium Brand LG SIGNATURE, LG Introduces Immersive Performancesat the LG Arts Center SEOUL
    SEOUL, South Korea, Nov. 27, 2022 /PRNewswire/ -- LG Electronics (LG) brought together the world of art and technology with its ultra-premium brand, LG SIGNATURE, sponsoring two immersive performances at the LG Arts Center SEOUL in South Korea last week.
  • The performance series well marks LG's time-old commitment to the cultivation of the arts beginning from the operation of the LG Arts Center SEOUL.
  • A testimony to LG's devotion to the arts, the relocated Center boasts a spacious, new performance venue, the LG SIGNATURE Hall.
  • During the Yoann Bourgeois series, visitors to LG Arts Center SEOUL were treated to an opportunity to enjoy the exclusive pop-up LG SIGNATURE exhibition and photo zone located in the LG SIGNATURE Hall lobby.

Cellares to tackle key roadblock in cell therapy manufacturing with new partner iVexSol

Retrieved on: 
Tuesday, September 20, 2022
Intelligence, Partnership, Patient, Eye, Automation, CEO, Technology, LVV, Solution, Robotics, SAN, Wine Cellar Innovations, Multimedia, Pharmaceutical industry, Vaccine, Fine chemical

SOUTH SAN FRANCISCO and LEXINGTON, Mass., Sept. 20, 2022 /PRNewswire/ --- Cellares Corporation, a life science technology company leading the way in cell therapy manufacturing automation, and iVexSol Inc., a company developing transformative viral vector manufacturing capabilities, today announced a strategic partnership to solve key challenges with viral vector manufacturing in order to accelerate access to life-saving therapies.

Key Points: 
  • Boasting an outstanding safety record, lentiviral vectors (LVV) are key components in CAR-T cell therapy manufacturing.
  • Cellares' automated, closed, end-to-end cell therapy manufacturing platform, the Cell Shuttle, can be easily adjusted to different customer processing needs and supports a variety of cell therapy modalities.
  • "We are thrilled by the opportunity to partner with the iVexSol team to broaden our capabilities while leveraging their tremendous expertise in viral vector manufacturing."
  • Cellares is creating the future of cell therapy manufacturing and accelerating access to life-saving cell therapies.